SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyson Foods, Inc. of Class Action Lawsuit and Upcoming Deadline – TSN

NEW YORK, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tyson Foods, Inc. (“Tyson” or the “Company”) (NYSE: TSN ) and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-08108, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Tyson securities between November 23, 2015 and October 6, 2016 inclusive (the “Class Period”).  This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). 

If you are a shareholder who purchased Tyson securities during the Class Period, you have until December 16, 2016 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com .   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

Tyson, together with its subsidiaries, operates as a food company worldwide. Through its Chicken segment, Tyson raises and processes chickens into fresh, frozen, and value-added chicken products.  The Company sells its products through its sales staff to grocery retailers, grocery wholesalers, meat distributors, warehouse club stores, military commissaries, industrial food processing companies, chain restaurants or their distributors, live markets, international export companies, and domestic distributors, as well as through independent brokers and trading companies.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) Tyson systematically colluded with several of its industry peers to fix prices in the broiler-chicken market; (ii) the foregoing conduct constituted a violation of federal antitrust laws; (iii) consequently, Tyson’s Chicken segment revenues during the class period were the result of illegal conduct; and (iv) as a result of the foregoing, Tyson’s public statements were materially false and misleading at all relevant times. 

On September 2, 2016, the market had its first inkling of Defendants’ fraud, when food distributor Maplevale Farms, Inc. (“Maplevale”) filed an antitrust class action complaint in U.S. District Court for the Northern District of Illinois against Tyson and several other poultry producers, including Pilgrim’s Pride Corporation, Perdue Farms, Inc., and Sanderson Farms, Inc., alleging that Tyson and the other companies named in the complaint had conspired since 2008 to manipulate the prices of broiler chickens—chickens raised specifically for meat production—by coordinating and limiting production and exchanging detailed information about prices, capacity, and sales volume, in violation of the Sherman Antitrust Act, 15 U.S.C. §§ 1-7 (the “Sherman Act”).

Between September 7, 2016 and October 7, 2016, eight more class action complaints were filed against Tyson and other poultry companies in the Northern District of Illinois, on behalf of individual consumers and indirect purchasers of broiler chickens, all alleging that Tyson had engaged in the price-manipulation scheme described in Maplevale’s complaint.

On October 7, 2016, Pivotal Research (“Pivotal”) downgraded Tyson from “Hold” to “Sell.”  Explaining the downgrade, analyst Timothy Ramey directed investors’ attention to the allegations of price manipulation by Tyson and its industry peers and described the Maplevale complaint as “powerfully convincing.”

On news of the downgrade, Tyson’s share price fell $6.63, or 8.91%, to close at $67.75 on October 7, 2016.  From the filing of the Maplevale action on September 2, 2016 to Pivotal’s downgrade on October 7, 2016, Tyson’s share price fell $8.69, or 11.37%.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com  

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 306

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 288

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 392

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 343

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 451

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 216

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 295

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Layne's Chicken Fingers Expands with Brownsville Opening

Updated Category News Views 289

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 487

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 152

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
d -->

Top 5 Most Recently Viewed Articles

Addressing the Housing Crisis: Federal Funding Efforts

Updated Category News Views 313

Tackling Canada's Housing Crisis Canada is actively working to combat its housing crisis, with significant measures aimed at helping those who are homeless. While there’s a sense of hope in the air, the presence of encampments underscores the immediate need for long-lasting solutions. The federal government is stepping up its efforts, showing a dedicated resolve to...

Continue Reading
Rigetti Computing Readies for Third Quarter Results Announcement

Updated Category News Views 65

Rigetti Computing Announces Third Quarter Financial Results Rigetti Computing, Inc. (Nasdaq: RGTI), recognized as a leader in hybrid quantum-classical computing, has exciting news regarding its financial performance. The company is set to release its financial results for the third quarter of 2024 on a specified date, marking an important moment for stakeholders and...

Continue Reading
Novartis Reports Outstanding Q3 Performance and 2025 Outlook

Updated Category News Views 545

Solid Q3 Performance by Novartis In a significant announcement, Novartis reported an impressive growth in net sales and core operating income for the third quarter. During this period, the company's net sales reached USD 13.9 billion, reflecting a growth of 7% on a constant currency basis and an 8% increase in USD terms. Core operating income showed a similar trajectory,...

Continue Reading
Forestar Group Inc. Set to Announce First Quarter Earnings Soon

Updated Category News Views 134

Forestar Group Inc. to Announce First Quarter Earnings Forestar Group Inc. (NYSE: FOR) is preparing to share key financial results for its first quarter, marking the end of December 2024. This eagerly awaited announcement will take place shortly before the markets open on the designated day. Shareholders and interested parties will have the opportunity to hear about the...

Continue Reading
ImCheck Therapeutics Secures EMA Orphan Drug Designation

Updated Category News Views 196

ImCheck Therapeutics Secures EMA Orphan Drug Designation ImCheck Therapeutics has exciting news as it recently announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to ICT01, its flagship treatment aimed at addressing acute myeloid leukemia (AML). This development, coming shortly after a similar designation from the U.S. FDA,...

Continue Reading